Crinetics Pharmaceuticals (CRNX) Research & Development (2017 - 2026)

Crinetics Pharmaceuticals' Research & Development history runs 10 years deep, the most recent figure standing at $100.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 31.27% year-over-year to $100.1 million; the TTM figure through Mar 2026 stood at $301.8 million (up 14.73% YoY), while the FY2025 annual figure was $332.1 million, up 38.27% from the prior year.
• Research & Development for Q1 2026 stood at $100.1 million, up from $85.1 million in the prior quarter.
• The five-year high for Research & Development was $100.1 million in Q1 2026, with the low at -$61.6 million in Q4 2022.
• The 5-year median for Research & Development is $45.6 million (2023), against an average of $48.1 million.
• The sharpest annual moves came in 2022 and 2023: Research & Development tumbled 350.25% in 2022, then jumped 174.03% in 2023.
• Crinetics Pharmaceuticals' Research & Development stood at -$61.6 million in 2022, then surged by 174.03% to $45.6 million in 2023, then surged by 46.04% to $66.6 million in 2024, then increased by 27.77% to $85.1 million in 2025, then advanced by 17.67% to $100.1 million in 2026.
• Business Quant data shows CRNX's Research & Development at $100.1 million in Q1 2026, $85.1 million in Q4 2025, and $90.5 million in Q3 2025.